| 词条 | Methylphenobarbital |
| 释义 |
| Watchedfields = changed | verifiedrevid = 462251506 | IUPAC_name = 5-Phenyl-5-ethyl-1-methylbarbituric acid | image = Methylphenobarbital.svg | width = 115 | tradename =Mebaral, generics | Drugs.com = {{drugs.com|international|methylphenobarbital}} | MedlinePlus = a605022 | pregnancy_US = D | legal_CA = Schedule IV | legal_DE = Rx-only/Anlage III | legal_US = Schedule IV | legal_UK = Class B | routes_of_administration = By mouth (tablets) | bioavailability = | protein_bound = 70–76% | metabolism = Liver | elimination_half-life = 34 hours | excretion = | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = 115-38-8 | ATC_prefix = N03 | ATC_suffix = AA01 | PubChem = 8271 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = DB00849 | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 7972 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 5NC67NU76B | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D00700 | ChEBI_Ref = {{ebicite|correct|EBI}} | ChEBI = 6758 | ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL = 45029 | C=13 | H=14 | N=2 | O=3 | molecular_weight = 246.3 g/mol | smiles = O=C1N(C(=O)NC(=O)C1(c2ccccc2)CC)C | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C13H14N2O3/c1-3-13(9-7-5-4-6-8-9)10(16)14-12(18)15(2)11(13)17/h4-8H,3H2,1-2H3,(H,14,16,18) | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = ALARQZQTBTVLJV-UHFFFAOYSA-N }} Methylphenobarbital (INN), also known as mephobarbital (USAN, JAN) and mephobarbitone (BAN), marketed under brand names such as Mebaral, Mephyltaletten, Phemiton, and Prominal, is a drug which is a barbiturate derivative and is used primarily as an anticonvulsant,[1] but also as a sedative and anxiolytic. It is the N-methylated analogue of phenobarbital and has similar indications, therapeutic value, and tolerability. Approval history
The company further stated in a letter on its website [2] that under the FDA's Unapproved Drugs Initiative, FDA is no longer willing to allow the drug to be grandfathered. A new drug application would have needed to have been submitted to gain marketing approval, which would have taken an estimated five years, during which time patients would be required to change their therapies in any case. The last available tablets bore an expiration date of March 31, 2012, and the drug will no longer be available in the US when supplies are depleted. OverdoseSymptoms of overdose of mephobarbital include confusion, decrease in or loss of reflexes, somnolence, fever, irritability, hypothermia, poor judgment, shortness of breath or slow/troubled breathing, slow heartbeat, slurred speech, staggering, trouble in sleeping, unusual movements of the eyes, weakness. See also
References1. ^{{Cite book | title = The Treatment of Epilepsy | edition = 2nd |editor1=S. D. Shorvon |editor2=David R. Fish |editor3=Emilio Perucca |editor4=W. Edwin Dodson | publisher = Blackwell | year = 2004 | isbn = 0-632-06046-8}} {{Anticonvulsants}}{{GABAAergics}}2. ^Letter from Lundbeck to prescribers 3 : Anticonvulsants|Barbiturates|GABAA receptor positive allosteric modulators |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。